Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lumiliximab + fludarabine + cyclophosphamide + rituximab
- Development stage
- Discontinued
- Lead developer
- Biogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This is a combination therapy that adds lumiliximab (an anti-CD23 chimeric monoclonal antibody) to the standard FCR regimen (fludarabine, cyclophosphamide, and rituximab) for the treatment of chronic lymphocytic leukemia (CLL). The combination was investigated based on preclinical data showing enhanced antitumor effects when lumiliximab was combined with fludarabine or rituximab. Initial phase 1/2 studies showed promising results with high complete response rates, but a subsequent randomized phase 2/3 trial (LUCID) failed to demonstrate significant improvement over FCR alone.
- Brand names
- Fludara (fludarabine)Cytoxan (cyclophosphamide)Rituxan (rituximab)None for lumiliximab
- Other names
- FCR plus lumiliximabLUCID
02
Targets
Beyond the preview
Go deeper on lumiliximab + fludarabine + cyclophosphamide + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lumiliximab + fludarabine + cyclophosphamide + rituximab.